| ISSN |
2220-3249 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Minireviews |
| Article Title |
Thymosin alpha 1: A comprehensive review of the literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Asimina Dominari, Donald Hathaway III, Krunal Pandav, Wanessa Matos, Sharmi Biswas, Gowry Reddy, Sindhu Thevuthasan, Muhammad Adnan Khan, Anoopa Mathew, Sarabjot Singh Makkar, Madiha Zaidi, Michael Maher, Renato Beas, Valeria Castaneda, Trissa Paul, John Halpern and Diana Baralt |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Donald Hathaway III, BSc, N/A, N/A, Division of Research and Academic AffairsDivision of Research and Academic Affairs, Larkin Health System, 7032 SW 62nd Avenue, South Miami, Florida 33143, United States. donald.hathaway@larkinhospital.com |
| Key Words |
Thymosin alpha 1; Thymalfasin; T lymphocytes; Immunomodulating; Infectious diseases; Immune deficiency |
| Core Tip |
Thymosin alpha 1 is a naturally occurring peptide in the human thymus, which has long been recognized for its immune-modulating properties. The synthetic analog of thymosin alpha 1 has various clinical applications, such as in infectious diseases, malignancies and in immunocompromised states. There is emerging data postulating that this peptide could be of benefit in the treatment of severe acute respiratory syndrome coronavirus-2 infection. We herein discuss the underlying knowledge, current clinical uses and results of recent studies of thymosin alpha 1. |
| Publish Date |
2020-12-11 08:19 |
| Citation |
Dominari A, Hathaway III D, Pandav K, Matos W, Biswas S, Reddy G, Thevuthasan S, Khan MA, Mathew A, Makkar SS, Zaidi M, Maher M, Beas R, Castaneda V, Paul T, Halpern J, Baralt D. Thymosin alpha 1: A comprehensive review of the literature. World J Virol 2020; 9(5): 67-78 |
| URL |
https://www.wjgnet.com/2220-3249/full/v9/i5/67.htm |
| DOI |
https://dx.doi.org/10.5501/wjv.v9.i5.67 |
